AUS
NZ
UK
CA
USA
IND
Nexalis Therapeutics has revealed important updates regarding its financing efforts and clinical trial progress. The company has ended discussions with Point8 Capital Pty Ltd concerning a new funding facility and successfully completed the Phase 1 trial for its drug candidate IRX-616a. These developments come as Nexalis reevaluates its clinical priorities and funding approaches.<\/p> <\/div>
Key Points<\/h3>
- Nexalis Therapeutics Ltd (NX1)<\/li>
- Terminated funding negotiations with Point8 Capital<\/li>
- IRX-616a Phase 1 trial concluded successfully with no serious adverse events<\/li>
- Received $490,000 from the R&D Tax Incentive<\/li>
- Investors should monitor updates on alternative financing and clinical development strategies<\/li>
<\/ul>
<\/div>
Funding Negotiations with Point8 Capital End Without Agreement<\/h2>
Nexalis Therapeutics announced the conclusion of its funding discussions with Point8 Capital Pty Ltd without reaching a formal agreement. This follows the cancellation of the remaining commitment under the existing LFO Facility by Linlithgow Family Office Pty Ltd.<\/p>
Despite substantial engagement, Nexalis was unable to finalize a funding arrangement with Point8 and is now exploring other funding options, though no significant negotiations are currently active.<\/p>
IRX-616a Phase 1 Trial Surpasses Expectations<\/h2>
The Phase 1 clinical trial of IRX-616a has successfully concluded, delivering results that exceeded expectations. No serious adverse events were reported, confirming the drug's safety and tolerability in healthy volunteers.<\/p>
The trial yielded valuable dose-ranging data that will guide the design of forthcoming patient studies, despite the temporary suspension of the study order with iNGENū CRO Pty Ltd.<\/p>
Reassessment of Clinical Development Plans<\/h2>
Due to funding constraints leading to the suspension of study orders for IRX-211 and IRX-616a, Nexalis is reviewing its clinical development priorities. The company is conducting an in-depth analysis of the IRX-211 Phase 2 trial to address recruitment and screening challenges, with potential protocol amendments under consideration.<\/p>
For IRX-616a, Nexalis intends to implement a more adaptable and cost-efficient Phase 2 trial design, possibly incorporating a proof of concept study. The SRX-25 program remains in the planning stage, focusing on finalizing the Phase 1 trial design in Australia.<\/p>
R&D Tax Incentive Receipt Enhances Cash Position<\/h2>
Nexalis has received $490,000 from the Research & Development Tax Incentive following the submission of its 2025 income tax return. This financial injection supports the company amid ongoing funding and development challenges.<\/p>
The R&D Tax Incentive remains a vital element of Nexalis's funding strategy, underpinning its research and development efforts.<\/p>
LFO Facility Cancellation Leaves Outstanding Funding<\/h2>
The cancellation of the LFO Facility by Linlithgow Family Office Pty Ltd has resulted in $1.6 million in outstanding eligible funding requests. Nexalis is actively working to resolve this matter with LFO to satisfactorily close the facility arrangements.<\/p>
Prior to cancellation, Nexalis had received $0.8 million from the LFO Facility and remains committed to securing the remaining funds.<\/p>
Strategic Emphasis on U.S. FDA Approval Pathways<\/h2>
Nexalis Therapeutics is concentrating on obtaining U.S. FDA approval for its drug candidates through expedited and cost-effective regulatory pathways, such as the 505(b)(2) process. This approach targets unmet needs in pain management and mental health.<\/p>
The company’s clinical indications have been selected in consultation with regulatory authorities, highlighting substantial economic potential for Nexalis and its shareholders.<\/p>
Investor Outlook and Upcoming Updates<\/h2>
Investors are encouraged to follow Nexalis for forthcoming updates as the company pursues alternative funding options and advances its clinical development programs. Nexalis is dedicated to providing timely information as new developments occur.<\/p>
With the successful completion of the IRX-616a Phase 1 trial and ongoing strategic reassessments, Nexalis is positioning itself to progress its drug candidates and achieve critical milestones within its development pipeline.<\/p>
Funding Negotiations with Point8 Capital End Without Agreement<\/h2>
Nexalis Therapeutics announced the conclusion of its funding discussions with Point8 Capital Pty Ltd without reaching a formal agreement. This follows the cancellation of the remaining commitment under the existing LFO Facility by Linlithgow Family Office Pty Ltd.<\/p>
Despite substantial engagement, Nexalis was unable to finalize a funding arrangement with Point8 and is now exploring other funding options, though no significant negotiations are currently active.<\/p>
IRX-616a Phase 1 Trial Surpasses Expectations<\/h2>
The Phase 1 clinical trial of IRX-616a has successfully concluded, delivering results that exceeded expectations. No serious adverse events were reported, confirming the drug's safety and tolerability in healthy volunteers.<\/p>
The trial yielded valuable dose-ranging data that will guide the design of forthcoming patient studies, despite the temporary suspension of the study order with iNGENū CRO Pty Ltd.<\/p>
Reassessment of Clinical Development Plans<\/h2>
Due to funding constraints leading to the suspension of study orders for IRX-211 and IRX-616a, Nexalis is reviewing its clinical development priorities. The company is conducting an in-depth analysis of the IRX-211 Phase 2 trial to address recruitment and screening challenges, with potential protocol amendments under consideration.<\/p>
For IRX-616a, Nexalis intends to implement a more adaptable and cost-efficient Phase 2 trial design, possibly incorporating a proof of concept study. The SRX-25 program remains in the planning stage, focusing on finalizing the Phase 1 trial design in Australia.<\/p>
R&D Tax Incentive Receipt Enhances Cash Position<\/h2>
Nexalis has received $490,000 from the Research & Development Tax Incentive following the submission of its 2025 income tax return. This financial injection supports the company amid ongoing funding and development challenges.<\/p>
The R&D Tax Incentive remains a vital element of Nexalis's funding strategy, underpinning its research and development efforts.<\/p>
LFO Facility Cancellation Leaves Outstanding Funding<\/h2>
The cancellation of the LFO Facility by Linlithgow Family Office Pty Ltd has resulted in $1.6 million in outstanding eligible funding requests. Nexalis is actively working to resolve this matter with LFO to satisfactorily close the facility arrangements.<\/p>
Prior to cancellation, Nexalis had received $0.8 million from the LFO Facility and remains committed to securing the remaining funds.<\/p>
Strategic Emphasis on U.S. FDA Approval Pathways<\/h2>
Nexalis Therapeutics is concentrating on obtaining U.S. FDA approval for its drug candidates through expedited and cost-effective regulatory pathways, such as the 505(b)(2) process. This approach targets unmet needs in pain management and mental health.<\/p>
The company’s clinical indications have been selected in consultation with regulatory authorities, highlighting substantial economic potential for Nexalis and its shareholders.<\/p>
Investor Outlook and Upcoming Updates<\/h2>
Investors are encouraged to follow Nexalis for forthcoming updates as the company pursues alternative funding options and advances its clinical development programs. Nexalis is dedicated to providing timely information as new developments occur.<\/p>
With the successful completion of the IRX-616a Phase 1 trial and ongoing strategic reassessments, Nexalis is positioning itself to progress its drug candidates and achieve critical milestones within its development pipeline.<\/p>
